Seeing the Future Through Science
UCI Beall Applied Innovation June 4, 2020 By Ethan Perez UCI company jCyte, Inc. has formalized an exclusive licensing contract with Japanese pharmaceutical company Santen Pharmaceutical. jCyte, founded by Dr. […]
BioWorld Santen inks $252M license to Jcyte ocular cell therapy May 8, 2020 By Michael Fitzhugh Keen to address a rare vision-limiting disorder endured […]
jCyte Inc. Enters into Ex-US Licensing and Commercialization Agreement for jCell Therapy with Global Ophthalmology Leader Santen Pharmaceutical jCyte to receive up to $252 million, […]
This article discusses the scope and purpose of the special designation for Regenerative Medicine Advanced Therapies (RMAT) created by the passage of the 21st Century Cures […]
Cell therapy company jCyte has announced results from a phase 1/2a clinical trial for its investigational product, jCell, in retinitis pigmentosa (RP). Presented by David […]
In the past few months, jCyte has made a number of important announcements. In December, we received an $8.3 million grant from the California Institute […]
May 2, 2017 – Cell therapy company jCyte announced that the U.S. Food & Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for […]
Phase 2b study will investigate safety and efficacy of retinitis pigmentosa therapy April 19, 2017 – Cell therapy company jCyte is launching a phase […]
The California Institute for Regenerative Medcine’s (CIRM’s) second annual Alpha Stem Cell Clinics Network symposium showcased how stem cell therapies are rapidly moving towards the […]
Developing groundbreaking therapies can be maddeningly slow, but jCyte recently took a big step forward, receiving an $8.3 million grant from the California Institute for […]